STRATEC Biomedical AG (DE:SBS)
XETRA:SBS
Top Page
STRATEC Biomedical
(XETRA:SBS)
Select Model
Select Model
Rating:49Neutral
Price Target:
€22.50
▲(0.45% Upside)
Action:ReiteratedDate:12/19/25
STRATEC Biomedical's overall stock score of 49 reflects a cautious outlook, driven primarily by weak financial performance (score: 47, weight: 40%), particularly in cash flow generation and declining revenue. Technical analysis (score: 42, weight: 30%) further weighs on the score with bearish price trends and momentum. A reasonable valuation (score: 65, weight: 20%) provides some support, while the mixed earnings call outlook (score: 50, weight: 10%) adds limited upside. Investors should monitor financial recovery and momentum shifts closely.
Positive Factors
Partnership Development
Expanding partnerships enhance market reach and provide collaborative opportunities, supporting long-term revenue growth and innovation.
Negative Factors
Supply Chain Disruptions
Ongoing supply chain issues can hinder product delivery and sales, impacting revenue and customer satisfaction over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Partnership Development
Expanding partnerships enhance market reach and provide collaborative opportunities, supporting long-term revenue growth and innovation.
Read all positive factors
STRATEC Biomedical (SBS) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€215.89M
Dividend Yield2.71%
Average Volume (3M)15.55K
Price to Earnings (P/E)58.0
Beta (1Y)1.37
Revenue Growth-1.64%
EPS Growth22.60%
CountryDE
Employees1,462
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.13
Shares Outstanding12,157,841
10 Day Avg. Volume11,323
30 Day Avg. Volume15,548
Financial Highlights & Ratios
PEG Ratio4.75
Price to Book (P/B)1.49
Price to Sales (P/S)1.41
P/FCF Ratio11.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€28.67Price Target Upside27.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)1.65
Revenue Forecast (FY)€272.10M
STRATEC Biomedical Business Overview & Revenue Model
Company Description
STRATEC Biomedical (SBS) is a leading provider of automation and instrumentation solutions for the medical technology and diagnostics industries. The company specializes in the development and production of complex systems used in laboratories and...
How the Company Makes Money
STRATEC Biomedical generates revenue primarily through the sale of its diagnostic systems and related services. The company has a diversified revenue model that includes several key streams: direct sales of equipment and instruments to laboratorie...
STRATEC Biomedical Earnings Call Summary
Earnings Call Date:Nov 07, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Apr 28, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook with both achievements and challenges. While there were positive developments in sales growth, partnership expansion, and financial optimization, significant challenges were faced due to supply chain disruptions, margin declines, and decreased net income.Positive Updates
New CFO Appointment
Tanja Bucherl has been appointed as the new CFO, bringing a strong financial background and team spirit to the organization.
Negative Updates
Supply Chain Disruptions
Supply chain interruptions impacted sales, particularly in the immunoassay franchise, causing delivery shortfalls.
Read all updates
Q3-2025 Updates
Positive
Negative
New CFO Appointment
Tanja Bucherl has been appointed as the new CFO, bringing a strong financial background and team spirit to the organization.
Read all positive updates
Company Guidance
In the 2025 financial results call, Stratec provided guidance indicating a flat top-line expectation for the year, matching the previous year's figures on a constant currency basis. The company anticipates an adjusted EBIT margin between 10% and 12%, but expects to end towards the lower end of this range due to product mix and ongoing supply chain issues. Despite these challenges, Stratec confirmed a 2.5% sales increase at constant exchange rates, reaching EUR 175.6 million for the first nine months. The adjusted EBIT margin for this period was 7.3%, down from 8.8% the previous year, largely due to a decline in the gross margin from 27.4% to 25.8%. The company also anticipates a notable improvement in earnings dynamics and a better tax rate in Q4, which should result in a full-year tax rate significantly below the previous 26.5%. Additionally, a successful closing of a EUR 125 million syndicated loan was highlighted, enhancing financial flexibility. The company remains focused on cost discipline, inventory management, and executing its development and partnership strategies to support future growth.STRATEC Biomedical Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
35
Negative
| Breakdown | TTM | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 256.91M | 257.62M | 270.41M | 274.63M | 287.33M | 250.10M |
| Gross Profit | 74.74M | 76.39M | 68.16M | 79.49M | 87.71M | 68.99M |
| EBITDA | 45.96M | 47.34M | 43.16M | 57.53M | 66.52M | 56.72M |
| Net Income | 15.65M | 16.02M | 15.37M | 29.22M | 39.96M | 25.18M |
Balance Sheet | ||||||
| Total Assets | 431.24M | 445.06M | 466.58M | 397.50M | 368.52M | 331.90M |
| Cash, Cash Equivalents and Short-Term Investments | 24.01M | 48.73M | 34.22M | 24.07M | 48.72M | 39.15M |
| Total Debt | 132.24M | 130.53M | 141.37M | 87.15M | 85.30M | 109.58M |
| Total Liabilities | 191.16M | 202.53M | 233.25M | 172.32M | 162.77M | 159.36M |
| Stockholders Equity | 240.08M | 242.53M | 233.33M | 225.18M | 205.76M | 172.54M |
Cash Flow | ||||||
| Free Cash Flow | 7.09M | 30.52M | 2.00M | -8.74M | 43.24M | 6.27M |
| Operating Cash Flow | 21.85M | 48.71M | 19.43M | 10.28M | 63.47M | 31.85M |
| Investing Cash Flow | -16.91M | -15.97M | -44.16M | -19.00M | -20.13M | -21.84M |
| Financing Cash Flow | -15.79M | -20.30M | 35.44M | -14.11M | -34.33M | 5.22M |
STRATEC Biomedical Technical Analysis
Negative
22.40
Price Trends
19.65
Negative
20.99
Negative
23.99
Negative
Market Momentum
-0.77
Positive
35.17
Neutral
23.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SBS, the sentiment is Negative. The current price of 22.4 is above the 20-day moving average (MA) of 18.22, above the 50-day MA of 19.65, and below the 200-day MA of 23.99, indicating a bearish trend. The MACD of -0.77 indicates Positive momentum. The RSI at 35.17 is Neutral, neither overbought nor oversold. The STOCH value of 23.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:SBS.
STRATEC Biomedical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €1.57B | 9.32 | 9.11% | 3.46% | 2.14% | 6.69% | |
65 Neutral | €914.83M | 19.58 | 20.78% | 1.11% | 9.64% | 35.18% | |
57 Neutral | €42.14B | 27.87 | 11.65% | 2.13% | 4.53% | 10.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | €215.89M | 58.01 | 6.55% | 2.71% | -1.64% | 22.60% | |
49 Neutral | €589.60M | -30.69 | 1.59% | 0.15% | 11.83% | -79.57% |
* Healthcare Sector Average
DE:SBS
STRATEC Biomedical
17.76
-4.09
-18.71%
DE:DRW8
Draegerwerk AG & Co. KGaA
75.00
27.49
57.87%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
14.62
-1.46
-9.05%
DE:SIS
First Sensor
55.00
-2.24
-3.91%
DE:GXI
Gerresheimer
17.07
-35.94
-67.80%
DE:SHL
Siemens Healthineers AG
37.77
-4.74
-11.15%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.